Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
Huiqiong Zeng, Hanjiang Liu, Zhi Liu, Xiakai Zhou, Xiaoping Lu, Zhenbo Yan, Yan Zhou, Liping Dai, Yashuo Chen, Tingting Yang, Zhihua Yin, Zhizhong Ye
Abstract
= .015) were independently associated with lower rises in the magnitude of COVID-19 vaccine antibodies. No vaccine-related serious adverse reactions were observed in either group. After receiving two doses of ICVs, the production of protective antibodies in stable RD patients treated with immunosuppressive agents may decrease. It was discovered that ICVs were safe and well tolerated by RD patients.
Topics & Concepts
ImmunogenicityMedicineVaccinationAdverse effectAntibodyImmunologyInternal medicineSARS-CoV-2 and COVID-19 ResearchDermatological and COVID-19 studiesHeparin-Induced Thrombocytopenia and Thrombosis